Kelly Goldsmith, M.D.

Director, Recurrent/Refractory Neuroblastoma Program

Egleston hospital

Assistant Professor of Pediatrics
Department of Pediatrics
Emory University School of Medicine

Biography Dr. Goldsmith's laboratory investigates the molecular mechanisms of chemotherapy resistance in pediatric neuroblastoma, focusing on experimental therapeutics that restore therapy sensitivity. Her research expertise is in apoptosis deregulation in cancer, the Bcl-2 family, and neurodevelopmental genes that play a role in therapy resistance. Her translational research provided the concept behind a first in pediatrics Phase I trial of simvastatin in combination with chemotherapy for recurrent solid/CNS tumors of childhood. She is co-chair of a NANT Precision Medicine Study for recurrent neuroblastoma and chair of the AflacST1402 trial. Dr. Goldsmith rounds out her bench to bedside personality as the clinical director of our Refractory and Recurrent Neuroblastoma Program where she and her team work to match a relapsed patient with the appropriate therapy for their recurrent disease.

Education and Training Medical Degree: University of Alabama School of Medicine, Birmingham, AL, 1995-1999
Residency: Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, 1999-2002
Fellowship: Pediatric Hematology/Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2002-2005


  • Pediatric Hematology/Oncology, American Board of Pediatrics
  • General Pediatrics, American Board of Pediatrics
Professional Scientific Societies
  • American Society of Pediatric Hematology and Oncology, Member
  • American Association for Cancer Research, Member
  • American Society of Clinical Oncology, Member
  • Children’s Oncology Group
    • Neuroblastoma committee
    • Renal Tumor Biology committee
    • Young Investigators committee
  • New Approaches to Neuroblastoma (NANT), Institutional PI

Publications / Presentations

Selected journal articles authored/co-authored by this physician are available at the National Library of Medicine's online resource PubMed.

  • Mentored Clinical-Scientist Training Award, K08, 2008-2012
  • American Recovery and Reinvestment Act Award, 2009-2011
  • CURE Childhood Cancer Foundation Award, 2009-present
  • Hyundai Hope on Wheels Scholar 2012, 2015
  • Advances in Neuroblastoma Research Meeting Award, Best Basic Science Abstract, 2014

Professional Interests
  • Neuroblastoma
  • Wilms tumor
  • Other renal tumors of childhood
  • Research interests: Basic and translational research for neuroblastoma, with a primary focus on mechanisms of therapy resistance

Privileges Egleston